Thirty-seven anaemic subjects with low-to -intermediate risk myelodysplastic syndrome (NIDS) received the highly glycosylated, long-acting erythropoiesis-stimulating molecule clarbepoetin-alpha (DPO) at the single, weekly dose of 150 mug s.c. for at least 12 weeks. Fifteen patients (40-5%) achieved an erythroid response (13 major and two minor improvements, respectively, according to International Working Group criteria). Such results are currently maintained after 7-22 months in 13 of the responders, one of whom required iron substitutive therapy during the treatment. One patient relapsed after 4 months. Another responder died after 5 months because of causes unrelated to the treatment. No relevant side-effects were recorded. At multivariate analysis, significant predictive factors of response were baseline serum levels of endogenous ery-thropoietin <100 IU/1, absent or limited transfusional needs, no excess of blasts and hypoplastic bone marrow. This study suggests that DPO, at the dose and schedule used, can be safely given in low-intermediate risk MDS and may be effective in a significant proportion of these patients.

Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplasic syndromes.

GHIO, RICCARDO;
2005

Abstract

Thirty-seven anaemic subjects with low-to -intermediate risk myelodysplastic syndrome (NIDS) received the highly glycosylated, long-acting erythropoiesis-stimulating molecule clarbepoetin-alpha (DPO) at the single, weekly dose of 150 mug s.c. for at least 12 weeks. Fifteen patients (40-5%) achieved an erythroid response (13 major and two minor improvements, respectively, according to International Working Group criteria). Such results are currently maintained after 7-22 months in 13 of the responders, one of whom required iron substitutive therapy during the treatment. One patient relapsed after 4 months. Another responder died after 5 months because of causes unrelated to the treatment. No relevant side-effects were recorded. At multivariate analysis, significant predictive factors of response were baseline serum levels of endogenous ery-thropoietin <100 IU/1, absent or limited transfusional needs, no excess of blasts and hypoplastic bone marrow. This study suggests that DPO, at the dose and schedule used, can be safely given in low-intermediate risk MDS and may be effective in a significant proportion of these patients.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11567/207559
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 90
  • ???jsp.display-item.citation.isi??? 73
social impact